Verily Life Sciences LLC and iRhythm Technologies Inc. have agreed to work together on technology for the diagnosis and management of atrial fibrillation.
The deal, announced 4 September, calls for iRhythm to pay Verily $5m upfront, plus up to $12.75m upon the achievement of various development and regulatory milestones.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?